Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gossamer Bio, Inc. (GOSS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), and its filings offer detailed insight into this strategy.
Through current reports on Form 8‑K, Gossamer Bio reports material events such as quarterly financial results, stockholder meeting outcomes, and significant transactions. Recent 8‑K filings have described results of operations and financial condition, approval of amendments to its 2019 Incentive Award Plan, and the option agreement and plan of merger that grant Gossamer Bio the right to acquire Respira Therapeutics and its pulmonary hypertension candidate RT234. These documents outline share issuances, potential milestone payments, and other key terms.
Investors can also use this page to locate references to the company’s incentive equity plans, employment inducement awards, and stockholder voting results, which appear in filings related to annual meetings and compensation arrangements. While Forms 10‑K and 10‑Q are not reproduced here, they are accessible through EDGAR and provide comprehensive information on research and development expenses, collaboration revenue, cash resources, and risk factors tied to seralutinib and the broader pipeline.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy reports, track how new equity issuances affect capital structure, and see how clinical and business milestones are reflected in Gossamer Bio’s regulatory record. Real-time updates ensure that new 8‑K, 10‑Q, 10‑K, and Form 4 insider transaction filings for GOSS are surfaced as they are posted to EDGAR, helping users follow the company’s evolving disclosure history.
Gossamer Bio, Inc. (GOSS) – Form 4 insider transaction
Director Thomas O. Daniel received an equity award on 06/25/2025 consisting of 115,000 non-qualified stock options with an exercise price of $1.36 and an expiration date of 06/24/2035. The grant was made under the company’s Non-Employee Director Compensation Program.
All options vest in full on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of shareholders, contingent on continued board service. The filing lists the transaction code “A” (acquisition) and shows 115,000 derivative securities beneficially owned directly after the transaction. No common shares were bought or sold.
- Standard director compensation; no immediate cash outlay by the insider.
- Filing signed on 06/26/2025 by Attorney-in-Fact Jeff Boerneke.
- No other changes in ownership disclosed.
Gossamer Bio director Steven D. Nathan received a stock option grant on June 25, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 115,000 stock options to purchase common stock
- Exercise price set at $1.36 per share
- Options expire on June 24, 2035
- Vesting occurs at the earlier of:
- First anniversary of grant date
- Next annual stockholder meeting
The award was made under the company's Non-Employee Director Compensation Program. Vesting is contingent on Nathan's continued service on the board of directors through the vesting date. The filing was submitted by attorney-in-fact Jeff Boerneke on June 26, 2025.
Form 4 filing for Gossamer Bio, Inc. (GOSS) discloses an option grant to director Russell J. Cox on 26 June 2025 (transaction date 25 June 2025).
- Instrument: Non-qualified stock option covering 115,000 common shares.
- Exercise price: $1.36 per share.
- Vesting: 100 % on the earlier of (a) the first anniversary of the 25 June 2025 grant date or (b) the next annual shareholder meeting, contingent on continued board service.
- Expiry: 24 June 2035 (10-year term).
- Ownership after grant: Cox holds 115,000 derivative securities; no change reported in underlying common-stock ownership.
- Purpose: Award issued under the company’s Non-Employee Director Compensation Program; no cash paid for the grant.
The filing represents routine director compensation with limited immediate balance-sheet impact. If exercised, the option would add a modest 115,000 shares to the company’s float, a de minimis level relative to Gossamer Bio’s total shares outstanding.
Gossamer Bio, Inc. (GOSS) filed a Form 4 disclosing that non-employee director John D. Quisel received a new stock-option award on 06/25/2025. The grant covers 115,000 options to purchase GOSS common shares at an exercise price of $1.36 per share. These options carry a ten-year term, expiring on 06/24/2035.
According to the issuer’s Non-Employee Director Compensation Program, the entire award vests on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of shareholders, provided the director remains on the board through the vesting date. No shares or options were sold or disposed of, and Quisel’s total beneficial holding of derivative securities increased to 115,000 options following the transaction. The filing indicates routine equity-based compensation and does not reference any 10b5-1 trading plan.
Form 4 overview: On 06/26/2025, Gossamer Bio, Inc. (GOSS) filed a Form 4 disclosing a routine equity award to outside director Sandra Milligan.
- Type of security: Non-qualified stock option covering 115,000 common shares.
- Grant date: 06/25/2025 | Exercise price: $1.36 per share.
- Vesting: 100 % on the earlier of (a) the first anniversary of the grant or (b) the next annual shareholder meeting, contingent on continued board service.
- Expiration: 06/24/2035 (10-year life).
- Ownership impact: Following the grant, Milligan beneficially owns 115,000 derivative securities; no common shares were bought or sold.
The grant was made under the company’s Non-Employee Director Compensation Program and reported under a standard transaction code “A” (grant without cash payment). Because this is a routine compensation award with no accompanying sale of shares or material change in ownership concentration, the filing is administrative and low-impact for investors.
Gossamer Bio, Inc. (GOSS) – Form 4 filing dated 06/26/2025
Non-employee director Skye Drynan received an option grant for 115,000 shares of common stock with an exercise price of $1.36 per share on 06/25/2025. The award was made under the company’s Non-Employee Director Compensation Program.
The option vests 100 % on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service. The director now beneficially owns 115,000 derivative securities; no common shares were reported as acquired or sold. Ownership is listed as direct.
No cash transactions, open-market purchases, or sales were disclosed. The filing represents a routine equity incentive and does not indicate any change in the company’s operational outlook or financial condition.
Form 8-K Overview: On 25 June 2025 Gossamer Bio (Nasdaq: GOSS) disclosed the voting results of its 2025 Annual Meeting and the adoption of an Amended & Restated 2019 Incentive Award Plan.
Board Elections: Class I directors Thomas Daniel, Sandra Milligan and Steven Nathan were re-elected for terms expiring in 2028. Support ranged from 80%–88% of votes cast, with 47.1 million broker non-votes recorded.
Auditor Ratification: Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal 2025 by 176.5 million votes for versus 0.1 million against, indicating near-unanimous confidence.
Say-on-Pay: Compensation of named executive officers received strong advisory backing—125.4 million for (≈96%) and 3.8 million against.
Equity Incentive Plan: The Amended & Restated 2019 Incentive Award Plan passed with 87.8 million for and 41.5 million against (≈67.7% approval, excluding broker non-votes). The comparatively higher dissent signals some shareholder concern over potential dilution or pay practices, though the proposal ultimately carried.
Materiality: No financial performance metrics, strategic transactions, or guidance updates were included. The filing is primarily governance-related; its impact centers on confirming board stability, auditor continuity and refreshed equity compensation capacity.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
